- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Peripheral nerve field.
Displaying page 1 of 1.
EudraCT Number: 2014-000848-14 | Sponsor Protocol Number: 38RC12.228 | Start Date*: 2014-07-23 |
Sponsor Name:Centre Hospitalier Universitaire de Grenoble | ||
Full Title: Endothelin and Ischemic optic Neuropathy study group | ||
Medical condition: Endothelin and Ischemic Optic Neuropathy study group | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000385-22 | Sponsor Protocol Number: RF-2010-2318561 | Start Date*: 2014-10-07 | ||||||||||||||||
Sponsor Name:Ospedale San Raffaele di Milano | ||||||||||||||||||
Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial. | ||||||||||||||||||
Medical condition: Retinitis pigmentosa with cystoid macular edema | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002204-27 | Sponsor Protocol Number: GS030_CLIN_001 | Start Date*: 2017-12-22 |
Sponsor Name:GENSIGHT-BIOLOGICS | ||
Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa | ||
Medical condition: Retinitis Pigmentosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000737-36 | Sponsor Protocol Number: 206207-015 | Start Date*: 2006-05-17 |
Sponsor Name:Allergan Limited | ||
Full Title: A 6-Week, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS... | ||
Medical condition: Non-infectious ocular inflammation of the anterior segment in anterior uveitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-004862-33 | Sponsor Protocol Number: BCBe/04/Neb-Gla/081 | Start Date*: 2006-05-23 |
Sponsor Name:Berlin-Chemie Menarini | ||
Full Title: INFLUENCE OF NEBIVOLOL ON OCULAR PERFUSION IN PATIENTS WITH ARTERIAL HYPERTENSION AND GLAUCOMA A mono-center, active-substance controlled, randomized, double-blind, prospective phase IV parallel-g... | ||
Medical condition: Arterial hypertension and glaucoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-005008-32 | Sponsor Protocol Number: ICORG13-17 | Start Date*: 2014-07-16 |
Sponsor Name:Cancer Trials Ireland | ||
Full Title: A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma | ||
Medical condition: Newly diagnosed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005294-60 | Sponsor Protocol Number: CRAD001C24114 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... | |||||||||||||
Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004668-71 | Sponsor Protocol Number: 11/0499 | Start Date*: 2014-09-25 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa | |||||||||||||
Medical condition: Childhood systemic polyarteritis nodosa (PAN) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) PT (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003145-17 | Sponsor Protocol Number: TH-CR-406/SARC021 | Start Date*: 2012-02-28 | |||||||||||
Sponsor Name:Threshold Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue S... | |||||||||||||
Medical condition: Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) HU (Completed) PL (Prematurely Ended) BE (Completed) IT (Completed) AT (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001186-20 | Sponsor Protocol Number: GEIS-83 | Start Date*: 2021-10-22 |
Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS | ||
Full Title: Phase Ib/II multicohort trial of different schemes of PM14 in monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors | ||
Medical condition: Advanced soft tissue sarcoma and other solid tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003643-31 | Sponsor Protocol Number: rg_13-022 | Start Date*: 2014-01-22 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Assessing the therapeutic efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension (IIH). | |||||||||||||
Medical condition: Idiopathic Intracranial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005175-27 | Sponsor Protocol Number: IB2017-01 | Start Date*: 2018-03-14 | ||||||||||||||||||||||||||
Sponsor Name:Institut Bergonié | ||||||||||||||||||||||||||||
Full Title: A phase I/II study of Regorafenib plus Avelumab in digestive tumors | ||||||||||||||||||||||||||||
Medical condition: Adult patients with advanced or metastatic digestive solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004750-15 | Sponsor Protocol Number: AIO-STS-0415 | Start Date*: 2017-10-06 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. | ||||||||||||||||||
Medical condition: advanced or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004426-10 | Sponsor Protocol Number: MO28072 | Start Date*: 2012-05-11 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual partici... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
